Please confirm that an ethics committee approval has been applied for or granted: Yes: I’m uploading the Ethics Committee Approval as a PDF file with this abstract submission

Application for ESRA Abstract Prizes: I apply as a Trainee/Resident/Fellow (no age limit)

Background and Aims Migraine is a common neurologic disorder posing a significant economic burden from absenteeism and medical treatments. Despite its considerable disease impact, no studies have directly aimed to survey those with this disease to quantify their disease burden through validated measures. Our study aims to provide quantitative values to the significance of their disease.

Methods Standard Gamble (SG), Time Trade-Off (TTO), and Visual Analog Scale (VAS) methods were used to quantify the health utility states of those with chronic migraine to determine Quality-Adjusted Life-Years (QALY). Monocular and binocular blindness utility scores were used as controls. Mass General Brigham Human Research Committee approved the IRB protocol.

Results A total of 39 patients with migraine were included in this study, with 31 (79.5%) female. The mean age was 45.9 years (SD=11.8). TTO utility scores for monocular blindness (0.92±0.09) and binocular blindness (0.79±0.17) compared to chronic migraine (0.73±0.26) showed they are significantly worse than monocular blindness (p =<0.01) and trended toward significance for binocular blindness (p=0.23). Given that the cited mean United States population utility for 45 – 54-year-olds is 0.82, migraine resolution would cause a 0.09 increase in healthy utility annually. This provides a calculated cost-effective threshold for a potential treatment of $279,000 per person over the remaining average lifetime, assuming a $100,000 willingness to pay per QALY.

Conclusions Our study is the first to systematically survey patients with migraine to present descriptive statistics to quantify the significance of their disease. Further studies are needed to quantify the quality-of-life improvement that occurs with various migraine treatments.